Physician profile
Shane Kelley
NPI 1891007605
$11,684.09
in general payments reported to CMS, 2019-2025
46 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $699 · 2021: $1,407 · 2022: $1,600 · 2023: $1,985 · 2024: $2,188 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,412.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,625.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,360.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,301.99 | 2019-2025 | |
| Abbvie INC. | $1,245.51 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.97 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $731.85 | 2019-2025 | Xifaxan |
| Amgen INC. | $678.05 | 2019-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $611.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $346.50 | 2021-2025 | |
| Lilly USA, LLC | $317.44 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $295.96 | 2019-2024 | Veozah |
| Abbott Laboratories | $206.59 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $196.41 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $190.53 | 2021-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $170.21 | 2023-2025 | Gvoke Hypopen |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.